Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc. - Common Stock (NQ: FENC )

6.130 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 Next >
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Earnings Scheduled For March 10, 2025
Via Benzinga
Fennec Pharmaceuticals's Earnings Outlook
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Preview: Fennec Pharmaceuticals's Earnings
Via Benzinga
Analyst Ratings for Fennec Pharmaceuticals
Via Benzinga
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
3 Dirt-Cheap Stocks Under $10 That Could EXPLODE!
These dirt cheap stocks under $10 have the potential to rise rapidly and create fortunes for bold investors. 
Via InvestorPlace
FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Recap: Fennec Pharmaceuticals Q1 Earnings
Via Benzinga
Earnings Outlook For Fennec Pharmaceuticals
Via Benzinga
Analyst Ratings for Fennec Pharmaceuticals
Via Benzinga
Expert Ratings for Fennec Pharmaceuticals
Via Benzinga
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. 
Via InvestorPlace
US Stocks Open Lower; Dow Dips 250 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.74% to 33,484.47 while the NASDAQ fell... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
Via Benzinga
4 Analysts Have This to Say About Fennec Pharmaceuticals
Via Benzinga
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
Where Fennec Pharmaceuticals Stands With Analysts
Via Benzinga
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Upgrades 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) announced that the U.S. 
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.